Literature DB >> 71993

Electrophoretic mobility (EM)-test for childhood cancer diagnosis.

U Nitzschke, T Zwergel, F Lampert.   

Abstract

Lymphocyte sensitization to myelin basic protein (encephalitogenic factor, EF) was determined in 193 children by measuring the electrophoretic mobility of indicator particles which had been incubated with the supernatant of the lymphocyte-antigen (EF) mixture. A significant decrease in electrophoretic migration time was found in 77 of 85 children with malignant tumours localized in brain, abdomen and extremities, in 36 of 38 children with acute lymphoblastic leukaemia (all except one in hematological remission), and in all 17 patients with lymphoma, in contrast to only 1 of 10 healthy children and 14 of 48 patients with non-malignant disorders. 10 of these 14 "false positive" patients, however, had auto-immune diseases. Thus, with false negative and false positive rates of less than 10%, this test could be of diagnostic help in patients with suspected malignant or auto-immune disease. Two examples of preoperative application of the EM-test are demonstrated.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 71993     DOI: 10.1007/BF00442198

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  12 in total

1.  [Demonstration of tumor-specific cellular immunity and blocking serum factors in children with neuro- and nephroblastoma using a new in-vitro test (Leukocyte adherence inhibition)].

Authors:  F Lampert; E Dietmair; K Guggenberger
Journal:  Monatsschr Kinderheilkd       Date:  1974-07

2.  [Application and significance of macrophage-electrophoretic-mobility-test (MEM) in neurological diseases (author's transl)].

Authors:  H Meyer-Rienecker; H L Jenssen; H Köhler; J Günther; H J Gundlach
Journal:  Klin Wochenschr       Date:  1974-05-15

3.  The macrophage electrophoretic migration test in cancer.

Authors:  A H Goldstone; L Kerr; W J Irvine
Journal:  Clin Exp Immunol       Date:  1973-07       Impact factor: 4.330

4.  Macrophage-electrophoretic-mobility (M.E.M.) test for malignant disease. An independent confirmation.

Authors:  J A Pritchard; J L Moore; W H Sutherland; C A Joslin
Journal:  Lancet       Date:  1972-09-23       Impact factor: 79.321

5.  Tumor-specific antigens detected by inhibition of macrophage migration.

Authors:  B S Kronman; H T Wepsic; W H Churchill; B Zbar; T Borsos; H J Rapp
Journal:  Science       Date:  1969-07-18       Impact factor: 47.728

6.  Lymphocyte sensitisation: an in-vitro test for cancer?

Authors:  E J Field; E A Caspary
Journal:  Lancet       Date:  1970-12-26       Impact factor: 79.321

7.  Macrophage electrophoretic mobility (MEM) test in cancer: a critical evaluation.

Authors:  E J Field; E A Caspary; K S Smith
Journal:  Br J Cancer Suppl       Date:  1973-08

8.  An assessment of the macrophage electrophoretic mobility test (MEM) in cancer diagnosis.

Authors:  E H Crozier; M E Hollinger; B E Woodend; J H Robertson
Journal:  J Clin Pathol       Date:  1976-07       Impact factor: 3.411

9.  Evaluation and development of the macrophage electrophoretic mobility (MEM) test for malignant disease.

Authors:  J A Pritchard; J L Moore; W H Sutherland; C A Joslin
Journal:  Br J Cancer       Date:  1973-01       Impact factor: 7.640

10.  Detection of anti-tumour cell mediated immunity and serum blocking factors in cancer patients by the leucocyte adherence inhibition test.

Authors:  W J Halliday; A Maluish; W H Isbister
Journal:  Br J Cancer       Date:  1974-01       Impact factor: 7.640

View more
  2 in total

1.  Cell electrophoresis for diagnostic purposes. II. Critical evaluation of conventional cytopherometry.

Authors:  W Hoffmann; R Kaufmann; R Steiner; W Werner
Journal:  Br J Cancer       Date:  1981-05       Impact factor: 7.640

2.  Effect of lymphocyte supernatants on the electrophoretic mobility of erythrocytes: significance in cancer diagnosis.

Authors:  J E Dyson; P J Corbett
Journal:  Br J Cancer       Date:  1978-09       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.